Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (811)	3/22/2006 11:12:33 AM
From: kenhott	Respond to of 946

Unfortunately most of my posts are not too clear. <These data suggest that in the relapsed setting, substituting pixantrone for doxorubicin can offer patients a high probability of achieving a complete remission not available with standard chemotherapy regimens and underscores the rationale for studying the CPOP regimen versus the CHOP regimen in first-line treatment of aggressive NHL," stated James A. Bianco, M.D., President and CEO of CTI.> I have a large problem with what comes out of his mouth. That was my only point.

To: D.Lu who wrote (811)	3/22/2006 11:14:36 AM
From: tuck	Respond to of 946

I'll let kenhott speak for himself, but I feel Bianco is being a little wild in suggesting the CPOP regimen should be studied in first line settings, based on these results. Unless Pix is going to be less expensive than dox, which it had better not be. I don't see insurers going for it unless it could handily beat standard of care, which, as the PR admits, has a pretty good track record. That said, it would expand the market for Pix if it could go into first line settings, but CTIC doesn't have the money to fund the trial, given its XYOTAX gamble. Cheers, Tuck